Web Research

The Bottom Line from the Web

The web adds one critical point that filings alone can understate: Centene's 2025 Marketplace miss is now a credibility and securities-litigation issue, not just an underwriting reset. The most important current question is whether the company can prove that 2026 rate actions and operating changes offset declining membership, elevated medical costs, and investor skepticism after the July 2025 guidance withdrawal. Sources: https://www.globenewswire.com/news-release/2025/09/02/3142789/32716/en/CNC-ALERT-Centene-CNC-Sued-as-Investors-Allege-Company-Concealed-Financial-Risks-Hagens-Berman.html; https://investors.centene.com/2026-02-06-CENTENE-CORPORATION-REPORTS-2025-RESULTS-AND-ANNOUNCES-2026-GUIDANCE

All figures are in USD.

April 24 Close

$41.82

Avg Target Est.

$43.47

FY2025 Revenue

$194.8B

FY2025 HBR

91.9%

**1. The 2025 guidance withdrawal became a litigation overhang.** A September 2, 2025 notice says the securities class action covers investors who bought from December 12, 2024 through June 30, 2025 and alleges Centene was too optimistic about Marketplace enrollment and morbidity before abruptly withdrawing 2025 guidance on July 1, 2025. The same notice says the stock fell more than 40% in one day and that the later Q2 diluted loss per share was -$0.51. Source: https://www.globenewswire.com/news-release/2025/09/02/3142789/32716/en/CNC-ALERT-Centene-CNC-Sued-as-Investors-Allege-Company-Concealed-Financial-Risks-Hagens-Berman.html

**2. The recovery plan begins from very high claims pressure.** Centene reported FY2025 total revenue of $194.8B, premium and service revenue of $174.6B, a GAAP diluted loss per share of $13.53, adjusted EPS of $2.08, and a full-year HBR of 91.9% versus 88.3% in 2024. The company blamed higher Marketplace morbidity, lower Marketplace risk-adjustment revenue, Medicare PDP program changes, and Medicaid cost pressure from behavioral health, home health, and high-cost drugs; FY2026 guidance calls for revenue of $186.5B-$190.5B, HBR of 90.9%-91.7%, and adjusted EPS greater than $3.00. Source: https://investors.centene.com/2026-02-06-CENTENE-CORPORATION-REPORTS-2025-RESULTS-AND-ANNOUNCES-2026-GUIDANCE

**3. The Q1 setup says the reset is not yet clean.** The April 24 Q1 preview estimates EPS of $1.85, down 36.2% year over year, revenue of $47.47B, up 1.8%, total membership down 7.4%, Medicaid membership down 5.1%, commercial membership down 35%, and HBR of 89.3% versus 87.1% a year earlier. That is a direct test of management's claim that 2026 can show margin repair. Source: https://www.ainvest.com/news/declining-memberships-weigh-centene-q1-earnings-2604/

**4. Management added experienced segment operators where the pressure is highest.** On April 6, 2026, Centene created two group-president roles reporting to CEO Sarah London: Daniel Finke, formerly CEO of Convey Health Solutions and previously president of Aetna at CVS Health, will oversee Medicaid and Commercial; Michael Carson, Wellcare CEO since January 2024, will oversee Medicare, Part D, Duals, and Specialty. Source: https://investors.centene.com/2026-04-06-Centene-Announces-New-Executive-Leadership-Structure

5. Analyst sentiment is mixed after the rebound. Yahoo showed a $41.82 April 24 close and a $43.47 one-year target estimate, while Fintel snippets cited a $47.42 average target and TickerNerd cited a $44 median target. Recent headlines are split: Jefferies Hold with a $39 target, Barclays Buy, JPMorgan target cut to $41, Goldman Sell with a $32 target, and Mizuho target cut to $41. Sources: https://finance.yahoo.com/quote/CNC/; https://fintel.io/s/us/cnc; https://tickernerd.com/stock/cnc-forecast/; https://www.cnn.com/markets/stocks/CNC

**6. Some value investors are leaning into the collapse, but institutions are divided.** A Yahoo-hosted Insider Monkey article says Greenlight Capital owned more than 2.6M shares at Q4 2025, up close to 70% from Q3 2025. Quiver's institutional feed also lists AQR adding 17.1M shares in Q4 2025, while Norges Bank, UBS Asset Management Americas, and Politan cut large positions. Sources: https://finance.yahoo.com/markets/stocks/articles/centene-corporation-cnc-david-einhorn-133713438.html; https://www.quiverquant.com/news/Lobbying+Update:+$1,030,000+of+CENTENE+CORPORATION+lobbying+was+just+disclosed

**7. Insider activity does not show insider buying support.** Quiver reports that CNC insiders made two open-market trades over the prior six months, both sales and no purchases; Kenneth Burdick sold 66,007 shares for an estimated $2.576M. Form 4 snippets also show tax-withholding and equity-award activity, which is not the same as discretionary buying. Sources: https://www.quiverquant.com/news/Lobbying+Update:+$1,030,000+of+CENTENE+CORPORATION+lobbying+was+just+disclosed; https://www.stocktitan.net/sec-filings/CNC/

**8. Policy risk is live in 2026.** Quote-page headlines cite ACA payment friction and subsidy-expiration stress, while April Medicare Advantage payment headlines were more favorable. Centene's Q1 2026 lobbying disclosure totals $1.03M and names individual-market affordability, Medicare Advantage, Part D, quality, and prior-authorization issues, which are the same policy levers that drive membership and margins. Sources: https://www.cnn.com/markets/stocks/CNC; https://www.quiverquant.com/news/Lobbying+Update:+$1,030,000+of+CENTENE+CORPORATION+lobbying+was+just+disclosed

**9. Governance mechanics look improved, but credibility is still on trial.** The 2022 governance package proposed immediate board declassification, shareholder special-meeting rights, and written-consent rights; Yahoo profile snippets also report an ISS Governance QualityScore of 1 as of April 1, 2026. That does not erase the 2025 disclosure credibility question, but it reduces the odds that the story is mainly weak governance mechanics. Sources: https://www.prnewswire.com/news-releases/centene-files-preliminary-proxy-statement-for-special-meeting-to-propose-enhanced-corporate-governance-provisions-301597298.html; https://finance.yahoo.com/quote/CNC/profile/

10. A past network-adequacy failure is worth remembering, not over-weighting. In 2017, Washington's insurance commissioner fined a Centene unit $1.5M and temporarily stopped sales after more than 140 complaints about inadequate provider networks; the unit admitted network inadequacy and monitoring failures. This is old, but it is relevant because provider-network adequacy is a repeat operating-risk theme for managed care. Source: https://www.cnbc.com/2017/12/15/centene-fined-1-point-5-million-can-resume-obamacare-sales-in-washington.html

Recent News Timeline

No Results

What the Specialists Asked

Insider Spotlight

Sarah M. London, CEO and director. London has been CEO since March 2022 and director since September 2021, according to the management-profile snippets. A third-party profile reports $20.60M of annual compensation, 6.8% salary and 93.2% variable/equity, and direct ownership of 0.052%; the corpus did not show discretionary open-market buying by London. Sources: https://simplywall.st/stocks/us/healthcare/nyse-cnc/centene/management; https://www.centene.com/who-we-are/board-of-directors.html

Daniel Finke and Michael Carson, new group presidents. The April 6, 2026 reorganization is the most important insider-development item: Finke brings Aetna/CVS and Convey Health Solutions experience to Medicaid and Commercial, while Carson expands from Wellcare CEO into Medicare, Part D, Duals, and Specialty. Source: https://investors.centene.com/2026-04-06-Centene-Announces-New-Executive-Leadership-Structure

Kenneth A. Burdick, director and former Centene executive. Burdick is listed on the board page as a former executive vice president of Products and Markets at Centene and former WellCare CEO. Quiver reports that he sold 66,007 shares for an estimated $2.576M over the prior six months, with no insider purchases reported for the company over that period. Sources: https://www.centene.com/who-we-are/board-of-directors.html; https://www.quiverquant.com/news/Lobbying+Update:+$1,030,000+of+CENTENE+CORPORATION+lobbying+was+just+disclosed

Andrew Asher and finance leadership. Form 4 snippets show a January 2026 equity award to Asher and March tax-withholding activity; the CNN feed also reports a March 19 controller change. These look like compensation and finance-leadership administration, not insider conviction buying. Sources: https://www.stocktitan.net/sec-filings/CNC/; https://www.cnn.com/markets/stocks/CNC

No Results

Industry Context

Centene is not just exposed to healthcare utilization; it is exposed to policy timing. Medicaid rates, ACA subsidy mechanics, Medicare Advantage payment updates, Part D redesign, and prior-authorization rules all flow quickly into enrollment, HBR, and investor confidence.

No Results

The practical implication is simple: the upside case is not generic healthcare demand, but successful repricing and operational cleanup after a disclosed cost/membership shock. The downside case is that Marketplace and Medicaid trend remains ahead of rate actions long enough to make the FY2026 EPS floor look fragile. Sources: https://investors.centene.com/2026-02-06-CENTENE-CORPORATION-REPORTS-2025-RESULTS-AND-ANNOUNCES-2026-GUIDANCE; https://www.ainvest.com/news/declining-memberships-weigh-centene-q1-earnings-2604/

Web Research

The Bottom Line from the Web

What Matters Most

Recent News Timeline

What the Specialists Asked

Insider Spotlight

Industry Context